Recent Updates
Recently added Catalysts
MGNX Negative Sentiment Score: 30/100

MacroGenics, Inc. Investors: Company Investigated by the Portnoy Law Firm

Monday, June 24, 2024 2 min read
Key Takeaway: MacroGenics, Inc. is under investigation by the Portnoy Law Firm for potential securities fraud, following significant losses suffered by investors. The law firm is considering filing a class action on behalf of affected shareholders. A recent announcement indicated serious safety concerns related to its Phase 2 TAMARACK study, highlighted by the unfortunate deaths of five patients. This news contributed to a drastic decrease in the company's stock price, which fell by 77.4% on May 10, 2024.

Market Sentiment Analysis

CONCERNS & RISKS

  • Investors are facing potential losses which may lead to a class action.
  • The company's stock price dropped significantly by 77.4% following safety concerns.
  • The recent death of five patients in a study raises serious concerns about the company's clinical trials.

Full Press Release Details

LOS ANGELES, June 24, 2024 (GLOBE NEWSWIRE) -- Investors can contact the law firm at no cost to learn more about recovering their losses
The Portnoy Law Firm advises MacroGenics, Inc. (“MacroGenics” or the “Company”) (NASDAQ: MGNX) investors that the firm has initiated an investigation into possible securities fraud and may file a class action on behalf of investors. MacroGenics investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq.
Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: lesley@portnoylaw.com, to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
On April 3, 2024, MacroGenics announced Phase 2 TAMARACK interim safety data as contained in its abstract submitted to the American Society of Clinical Oncology on February 6, 2024. The Company reported that “[p]reliminary safety data from TAMARACK suggest that reducing the dose and frequency of vobra duo improves its safety and tolerability in men with mCRPC.” Then, on May 10, 2024, MacroGenics revealed that five patients in the TAMARACK study had died.
On this news, MacroGenics’ stock price fell $11.36 per share, or 77.4%, to close at $3.31 per share on May 10, 2024.
Please visit our website to review more information and submit your transaction information.
The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.
Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
lesley@portnoylaw.com
Attorney Advertising

Tags

Breach of Fiduciary Duty

Frequently Asked Questions

What is the Portnoy Law Firm offering to MacroGenics investors?

The Portnoy Law Firm offers a no-cost consultation for MacroGenics investors to explore recovering their losses.

What prompted the investigation into MacroGenics, Inc.?

The investigation follows reports of possible securities fraud related to safety data announced by MacroGenics.

How did MacroGenics' stock perform after safety data was released?

MacroGenics' stock fell by 77.4%, closing at $3.31 per share following the release of troubling safety data.

How can investors contact the Portnoy Law Firm?

Investors can reach attorney Lesley Portnoy at 310-692-8883 or via email at lesley@portnoylaw.com.

What kind of compensation has the Portnoy Law Firm secured previously?

The Portnoy Law Firm has recovered over $5.5 billion for investors affected by corporate misconduct.

Tags: MGNX Viatris Investor Conferences Healthcare MacroGenics clinical trial PAMARACK securities fraud
Last updated: Jun 24, 2024